MKResearcher profile · from public sources
Marina Konopleva
Targets
Filled chips are declared by the researcher; the others come from publications (number of works).
Now
Trials, publications and grants since Nov 2024.
Publication
CC-486 plus venetoclax: another step toward oral AML therapy.
Blood advances, Oct 2026
Publication
Long-term outcomes of azacitidine, venetoclax, and gilteritinib in newly diagnosed FLT3-mutated AML.
Blood advances, Sept 2026
Publication
LY3410738, a Covalent Inhibitor of Mutant IDH1/2, Is Effective in Acute Myeloid Leukemia Preclinical Models.
Blood cancer discovery, Sept 2026
Publication
Genomic Subtype Influences BH3 Mimetic Drug Sensitivity and Synergy with Cytotoxic Chemotherapeutics in T-cell Acute Lymphoblastic Leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research, Jul 2026
Publication
CD64 enables TCR-dependent, MHC-independent CTL cytotoxicity of AML cells.
Proceedings of the National Academy of Sciences of the United States of America, Jul 2026
Publication
Anti-apoptotic BCL-2 family proteins: from regulatory networks to therapeutic targeting.
Oncogenesis, Jun 2026
Publication
A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemia.
Leukemia, Feb 2026
Publication
TP53 loss traps AML in XPO7-NPAT nuclear transport fraud.
Blood, Feb 2026
Publication
Rapid clonal selection within early hematopoietic cell compartments presages the outcome of ivosidenib combination therapy.
Blood, Feb 2026
Publication
Correction: Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.
Leukemia, Jan 2026
Publication
Blastic plasmacytoid dendritic cell neoplasm (BPDCN): international, multi-center collaboration and global registry program.
Discover oncology, Dec 2025
Publication
The LSC17 score: a prognostic biomarker now validated for real-world clinical application in acute myeloid leukemia.
Haematologica, Dec 2025
Publication
A phase 1/2 study of DS-1594 menin inhibitor in relapsed/refractory acute leukemias.
Journal of hematology & oncology, Nov 2025
Publication
Menin inhibitor DS-1594b drives differentiation and induces synergistic lethality in combination with venetoclax in acute myeloid leukemia cells with rearranged mixed-lineage leukemia and mutated nucleophosmin-1.
Haematologica, Nov 2025
Publication
Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis.
Clinical cancer research : an official journal of the American Association for Cancer Research, Jun 2025
Publication
Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Jun 2025
Publication
VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome: long term follow-up of a phase 2 trial.
Blood cancer journal, Apr 2025
Publication
DNTT-mediated DNA damage response drives inotuzumab ozogamicin resistance in B-cell acute lymphoblastic leukemia.
Blood, Mar 2025
Publication
Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia.
Blood advances, Feb 2025
Co-authors
Who links you
Enter another researcher's profile link or ID to see who has published with both of you.
You have published with Guilin Tang directly.
Is this you? Request a correction or removal: support@frontlightresearch.com
Report an error